Recent proof-of-concept studies were performed for breast, cervical, and ovarian cancer showing anti-tumor effects of CXCR4 antagonists (in combination with conventional therapy) in vivo (Table 4) [243, 266–268]. Here, CXCR4 is linked to neoplasm.